IECM
IBB icon

Intrinsic Edge Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Intrinsic Edge Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$4.12M – 172
2024
Q1 		$4.12M Buy
+30,000
New +$4.1M 0.32% 92

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Intrinsic Edge Capital Management's IBB Position: Q2 2024 in Review

Intrinsic Edge Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 30,000 shares — an estimated $4.12M sold.

Intrinsic Edge Capital Management first reported a position in IBB in Q1 2024 and held it in 1 quarter. The position peaked at $4.12M in Q1 2024. 896 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

  • Intrinsic Edge Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 30,000 iShares Biotechnology ETF shares in Q2 2024, an estimated $4.12M.
  • Intrinsic Edge Capital Management first reported a position in iShares Biotechnology ETF in Q1 2024 and held it in 1 quarter.
  • Intrinsic Edge Capital Management's iShares Biotechnology ETF position peaked at $4.12M in Q1 2024.
  • 896 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on Intrinsic Edge Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.